Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06699329 · ClinicalTrials.gov registry record · Phase 1
A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT06699329 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 38 participants.
The verdict
NCT06699329, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The goal of this study is to learn what happens in a person's body over time when they take enlicitide decanoate and semaglutide alone or at the same time. Enlicitide decanoate is a new medicine that lowers the amount of cholesterol in a person's blood. Semaglutide is a drug used to treat type 2 diabetes. Researchers want to learn what happens to the amount of semaglutide and enlicitide decanoate in a person's blood when each drug is taken alone and when they are taken together.
Interventions
- DRUG Semaglutide
- DRUG Enlicitide Decanoate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2024-01-22 |
| Est. Completion | 2024-05-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06699329
The ClinicalTrials.gov registry entry for NCT06699329 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Semaglutide is the first listed.
NCT06699329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06699329 about?
NCT06699329 is a clinical study titled "A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)". The goal of this study is to learn what happens in a person's body over time when they take enlicitide decanoate and semaglutide alone or at the same time. Enlicitide decanoate is a new medicine that lowers the amount of cholesterol in a person's blood. Semaglutide is a drug used to treat type 2 dia...
What is the current status of trial NCT06699329?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2024-01-22. Estimated completion is 2024-05-24.
What interventions are being tested in trial NCT06699329?
The interventions under investigation include: Semaglutide (DRUG), Enlicitide Decanoate (DRUG).
Who is sponsoring clinical trial NCT06699329?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.